 This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug SGN-15 with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the study is to determine the safety and clinical benefit, as measured by tumor response and quality of life, to the combination regimen. 